ENTOD’s Proprietary Ophthalmic Preservative System for Eye Drops

Mumbai, 19th July 2024: Mumbai-based pharmaceutical company ENTOD Pharmaceuticals has developed an innovative eye drop preservative system called EyeBS™️ that eliminates the need for harmful detergent-based preservatives such as Benzalkonium Chloride (BAK) and Polyquaternium-1 that are traditionally used in eye drop formulations, ensuring safety and efficacy while minimizing adverse reactions.

The EyeBS™️ proprietary preservative system is based on an ionic buffer containing a unique blend of borate, sorbitol, propylene glycol and zinc, and doesn’t cause any cytotoxic side effects as seen with conventional detergent-based ophthalmic preservatives.

This unique preservative system functions as an oxidizing preservative with both antibacterial and antifungal properties. It effectively and safely maintains the sterility of ophthalmic solutions throughout its shelf life without harming ocular tissues, making it a safe option for long-term use. Apart from strong antimicrobial protection it also offers excellent biocompatibility with ocular tissues.

The use of EyeBS™️ in eye drops also significantly reduces the risk of irritation, dryness, and other ocular surface disorders commonly associated with prolonged use of conventional detergent-based ophthalmic preservatives.

The efficacy, comfort and biocompatibility of the EyeBS™️ preservative system has been shown in various formulations and clinical studies worldwide, and approved by drug regulators in several countries.

Mrs Bharati S Jadhav, Senior Scientific Manager at Entod Pharmaceuticals, expressed her excitement, saying, “Such a transformative approach in maintaining the sterility of eye drops whilst prioritising patient safety and comfort without compromising efficacy marks a new era in the technology for eye drops. The expertise, dedication and perseverance of our formulation research team has allowed us to successfully develop this preservative system for eye drops that meets all global standards.”

ENTOD Pharmaceutical’s CEO Mr Nikkhil K Masurkar said, “This is indeed an exciting development in the field of eye drop technology. ENTOD Pharmaceuticals have been pioneers of eye drop preservative systems whether it’s the development of the safer and disappearing biodegradable ocular preservative Stabilized Oxychloro complex (SOC) way back in 2010 or the more recent EyeBS™️ preservative system in 2024. EyeBS preserved eye drops will be exclusively marketed and sold by ENTOD Pharmaceuticals, and the commercialisation of such eye drops is already under way.”